GlassScriptPhysician profile
Jay Bradley Lankford
NPI 1831753540
$4,174.32
in general payments reported to CMS, 2019-2025
29 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $246 · 2023: $1,650 · 2024: $1,174 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,881 · Education: $47.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,881.11 |
| Education | $47.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $733.97 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $602.54 | 2022-2025 | |
| Glaxosmithkline, LLC. | $512.98 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $268.93 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $265.31 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.92 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $180.53 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $175.29 | 2022-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.67 | 2022-2025 | Caplyta |
| Pfizer INC. | $135.05 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $100.92 | 2022-2023 | Quviviq |
| Amgen INC. | $98.44 | 2023-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $84.21 | 2023-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.21 | 2023-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $72.34 | 2024-2025 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $70.24 | 2023-2025 | Azstarys |
| Sumitomo Pharma America, INC. | $67.59 | 2023-2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $59.49 | 2023 | |
| Abbott Laboratories | $50.35 | 2023-2024 | Freestyle Libre, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $47.34 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $46.66 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $30.39 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.65 | 2023 | |
| Seqirus USA INC | $21.42 | 2025 | Fluad, Flucelvax |
| Collegium Pharmaceutical, INC. | $19.54 | 2025 | Jornay Pm |
| Xeris Pharmaceuticals, INC. | $18.23 | 2024 | Gvoke Hypopen |
| Atricure, INC. | $17.89 | 2025 | Atriclip Laa Exclusion System |
| Kowa Pharmaceuticals America, INC. | $12.82 | 2023 | Seglentis, Livalo |
| Endogastric Solutions, INC | $11.40 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Lankford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.